TROVE2 His Human is expressed in Escherichia coli and purified using chromatographic methods. Variants differ in buffer composition and tag placement:
N-terminal His-tagged versions (e.g., PRO-110, A113426): Optimized for ELISA and biotinylation .
C-terminal His-tagged versions (e.g., PRO-329): Stabilized in urea-based buffers for denaturing conditions .
TROVE2 His Human serves as a critical antigen in autoimmune disease studies and cancer research:
ELISA: Coating concentration: 0.2–0.5 µg/ml. Detects anti-TROVE2 autoantibodies in systemic lupus erythematosus (SLE) and Sjögren’s syndrome (SS) patient sera .
Western Blot: Validated with SLE sera or anti-His-tag antibodies .
A 2024 study identified TROVE2 as a driver of hepatocellular carcinoma (HCC) metastasis via the HPSE/GSK-3β/Snail signaling axis :
Process | TROVE2 Overexpression Effect | TROVE2 Knockdown Effect |
---|---|---|
Cell Invasion | ↑↑ (Transwell assay) | ↓↓ |
EMT Markers | ↑ N-cadherin, vimentin; ↓ E-cadherin | ↓ N-cadherin, vimentin; ↑ E-cadherin |
GSK-3β Phosphorylation | ↑ p-GSK-3β (inhibition of GSK-3β activity) | ↓ p-GSK-3β |
TROVE2 is a primary autoantigen in SLE and SS, with sera from patients targeting its RNA-binding domains. The His-tagged protein is used to:
In HCC, TROVE2 upregulation correlates with poor prognosis. Mechanistically, it binds heparanase (HPSE), promoting epithelial-to-mesenchymal transition (EMT) through:
The Human Recombinant TROVE2 is produced in Escherichia coli (E. coli) and is a single, non-glycosylated polypeptide chain with a molecular mass of approximately 60 kDa . The recombinant protein is fused with a 6 amino acid His-Tag at the C-terminus, which facilitates its purification through proprietary chromatographic techniques .
TROVE2, or Ro 60 kDa autoantigen, binds to Y RNAs and may stabilize these RNAs from degradation . This stabilization is crucial for the proper functioning of cellular processes. The protein is also known to be involved in autoimmune responses, as sera from patients with Systemic Lupus Erythematosus (SLE) often contain antibodies that react with the normal cellular SSA2 protein .